Quality of Life Assessed With the PAH SYMPACT Questionnaire in the Pulmonary Hypertension Clinic
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Pulmonary Hypertension
- Sponsor
- Mayo Clinic
- Enrollment
- 390
- Locations
- 1
- Primary Endpoint
- Quality of life in pulmonary hypertension subjects
- Status
- Completed
- Last Updated
- 9 months ago
Overview
Brief Summary
Researchers are evaluating quality of life in pulmonary hypertension subjects using the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire and assessing the questionnaires' performance with regard to relationship to other markers of disease severity, response to treatment, and outcome in a clinical practice setting.
Detailed Description
Subjects will be recruited from among those seen at the Mayo Pulmonary Hypertension Clinic. The PAH-SYMPACT questionnaire will be administered either in written form or by telephone interview. On the second 100 patients implement a standardized palliative care referral program for patients with Group 1 and 3 PH and high SYMPACT scores\> 1.0.
Investigators
Hilary M. DuBrock, MD
Principal Investigator
Mayo Clinic
Eligibility Criteria
Inclusion Criteria
- •Age 18 years or above
- •Consents to participate
- •Documented group I PAH based upon these hemodynamic criteria: (mPAP \> 20, PCW 18 or less, PVR \> 3 Wood units
- •Mean PAP \> 20, PCW ≤ 18, PVR \> 3 Wood units
- •Parenchymal lung disease that in the opinion of the investigator qualifies patient as group III PH
- •Documented chronic thromboembolic pulmonary hypertension or chronic thromboembolic disease with intent to treat with surgery, balloon pulmonary angioplasty, and/or PH medication
Exclusion Criteria
- •Left sided heart disease (LVEF\<50%, PAWP\>18)
- •Any other known concomitant life-threatening disease with a life expectancy \<12 months
- •Any other clinically relevant and/or serious chronic medical condition that would affect study participation in the opinion of the investigator
- •Non English speaking
Outcomes
Primary Outcomes
Quality of life in pulmonary hypertension subjects
Time Frame: 14 months
Measured using the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire using a scale of 0=no, 1=mild, 2=moderate, 3=severe, and 4=very severe